Emerging evidence and treatment paradigm of non-small cell lung cancer

• Published in: Journal of hematology and oncology Vol. 16; no. 1; pp. 40 - 20
• Main Authors: Liu, Si-Yang Maggie, Zheng, Mei-Mei, Pan, Yi, Liu, Si-Yang, Li, Yangqiu, Wu, Yi-Long
• Format: Journal Article
• Language: English
• Published: London BioMed Central 17.04.2023; BioMed Central Ltd; BMC
• Subjects: B7-H1 Antigen; Cancer Research; Cancer therapies; Carcinoma, Non-Small-Cell Lung - drug therapy; Care and treatment; Chemotherapy; Clinical trials; FDA approval; Hematology; Humans; Immune checkpoint inhibitors; Immunotherapy; Immunotherapy - methods; Lung cancer; Lung cancer, Non-small cell; Lung cancer, Small cell; Lung Neoplasms - drug therapy; Medicine; Medicine & Public Health; Mutation; Non-small cell lung carcinoma; Oncology; Programmed Cell Death 1 Receptor; Review; Small cell lung carcinoma
• ISSN: 1756-8722; 1756-8722
• DOI: 10.1186/s13045-023-01436-2

Research on biomarker-driven therapy and immune check-point blockade in non-small cell lung cancer (NSCLC) is rapidly evolving. The width and depth of clinical trials have also dramatically improved in an unprecedented speed. The personalized treatment paradigm evolved every year. In this review, we summarize the promising agents that have shifted the treatment paradigm for NSCLC patients across all stages, including targeted therapy and immunotherapy using checkpoint inhibitors. Based on recent evidence, we propose treatment algorithms for NSCLC and propose several unsolved clinical issues, which are being explored in ongoing clinical trials. The results of these trials are likely to impact future clinical practice.